Drug Eluting Stent Market Report 2025

This Drug Eluting Stent market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The drug eluting stent market size has grown strongly in recent years. It will grow from $7.63 billion in 2024 to $8.29 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to the need for improved treatment options, clinical evidence, regulatory approval, healthcare economics, and guidelines and recommendations.

The drug eluting stent market size is expected to see strong growth in the next few years. It will grow to $11.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to an aging population and chronic disease burden, the expansion of indications, healthcare reimbursement policies, global market expansion, and patient-centered care. Major trends in the forecast period include personalized medicine, minimally invasive techniques, emerging healthcare technologies, and next-generation drug formulations.

The rising levels of water pollution are expected to drive the growth of the ecotoxicological studies market in the coming years. Water pollution refers to the contamination of water bodies, such as rivers, lakes, oceans, and groundwater, by harmful pollutants, which negatively impact human health, aquatic life, and the environment. The increasing pollution is driven by factors like industrial discharges, agricultural runoff containing fertilizers and pesticides, improper waste disposal, urbanization causing sewage contamination, and oil spills. Ecotoxicological studies assess the toxicity of pollutants, such as chemicals, heavy metals, and other contaminants, on aquatic organisms, helping to develop pollution control strategies to reduce the harmful effects of water pollution. For example, data from Buckingham Futures in August 2024 reported that sewage spills in England's rivers and seas totaled 1.75 million hours in 2022, which increased to 3.6 million hours in 2023. As a result, the growing water pollution is fueling the demand for ecotoxicological studies.

Companies operating in the drug-eluting stent market are directing their efforts toward developing innovative delivery systems, such as the dual-layer balloon, to enhance patient outcomes and advance interventional cardiology. A dual-layer balloon within a drug-eluting stent system improves precision in drug delivery and stent deployment by offering better control and uniform drug application to the arterial wall. For instance, in August 2022, Medtronic Plc introduced Onyx Frontier, the latest generation of drug-eluting coronary stent systems designed to enhance delivery systems, building upon the acute performance and clinical data from the previous Resolute Onyx DES generation. The Onyx Frontier DES utilizes the same high-quality stent platform as Resolute Onyx and features a wide size range to treat patients with diameters ranging from 2.0mm to 5.0mm. Notable design enhancements include a groundbreaking dual-layer balloon, reduced crossing profile, and enhanced catheter flexibility, resulting in a 16% increase in deliverability compared to the previous Resolute Onyx DES generation, while maintaining radial strength.

In October 2023, Cordis acquired MedAlliance for an undisclosed sum. This acquisition is aimed at furthering Cordis' tradition of cardiovascular innovation and expanding its product portfolio in the coronary and peripheral vascular markets. MedAlliance is a Switzerland-based medical device manufacturer and distributor specializing in drug-eluting stents.

Major companies operating in the drug eluting stent market are Johnson & Johnson Services Inc., Abbott, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, InspireMD Inc., B. Braun Melsungen AG, Cook Group Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Biotronik, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Company Limited, Alvimedica Medical Technologies, Hexacath, Elixir Medical Corporation, Translumina GmbH, Cardionovum GmbH, QualiMed Innovative Medizinprodukte GmbH, InSitu Technologies Inc., Acrostak AG, SINOMED Innovation Inc., Svelte Medical Systems Inc.

North America was the largest region in the drug-eluting stent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug eluting stent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A drug-eluting stent (DES) is a medical device employed in the treatment of coronary artery disease (CAD). It constitutes a small, mesh-like tube typically constructed from metal, which is inserted into narrowed or blocked coronary arteries during a procedure known as percutaneous coronary intervention (PCI) or angioplasty.

The primary product types of drug-eluting stents include polymer-based and polymer-free varieties. Polymer-based drug-eluting stents (DES) are stents coated with a thin polymer layer that encapsulates the drug(s) intended for delivery to the arterial wall. These drugs may include sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, among others, with scaffolds such as cobalt-chromium, platinum-chromium, nitinol, biodegradable materials, and others. They find application in coronary diseases and peripheral vascular disease and are utilized by end-users such as hospitals and specialty clinics.

The drug eluting stent market research report is one of a series of new reports that provides drug eluting stent market statistics, including drug eluting stent industry global market size, regional shares, competitors with a drug eluting stent market share, detailed drug eluting stent market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting stent industry. This drug eluting stent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug eluting stent market consists of revenues earned by entities by providing services such as pre-procedural assessment, procedural intervention, intraoperative monitoring, post-procedural care, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug eluting stenting market also includes sales of products including guide wires, angioplasty equipment, intravascular imaging systems, hemostasis devices, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.